The mission of the Company is to develop innovative and revolutionary treatments to combat disorders caused by disruption of neuronal signaling. We are developing treatment options that address conditions that affect millions of people, but for which there are limited or poor treatment options, including obstructive sleep apnea (“OSA”), attention deficit hyperactivity disorder (“ADHD”) epilepsy, chronic pain, spinal cord injury (“SCI”).

RespireRx is developing a pipeline of new drug products based on our broad patent portfolios across two distinct drug platforms:

1. ResolutionRx, our pharmaceutical cannabinoids platform, is developing compounds that target the body’s endocannabinoid system, and in particular, the re-purposing of dronabinol, an endocannabinoid CB1 and CB2 receptor agonist, for the treatment of OSA. Dronabinol is already approved by the FDA for other indications.

2. EndeavourRx, our neuromodulators platform including (a) AMPAkines that are positive allosteric modulators (“PAMs”) of AMPA-type glutamate receptors and (b) GABAkines that are PAMs of GABAA receptors.